Larimar Therapeutics Inc (NASDAQ:LRMR) shares, rose in value on Friday, July 11, with the stock price down by -2.87% to the previous day’s close as strong demand from buyers drove the stock to $3.38.
Actively observing the price movement in the last trading, the stock closed the session at $3.48, falling within a range of $3.3412 and $3.48. The value of beta (5-year monthly) was 0.79. Referring to stock’s 52-week performance, its high was $11.20, and the low was $1.61. On the whole, LRMR has fluctuated by 16.15% over the past month.
With the market capitalization of Larimar Therapeutics Inc currently standing at about $216.42 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Apr-30.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that LRMR’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium-term indicators have put the stock in the category of Hold while long-term indicators on average have been pointing out that it is a Hold.
The stock’s technical analysis shows that the price of LRMR currently trading nearly 11.94% and 31.25% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 63.61, while the 7-day volatility ratio is showing 6.42% which for the 30-day chart, stands at 10.26%. Furthermore, Larimar Therapeutics Inc (LRMR)’s beta value is 0.93.
A comparison of Larimar Therapeutics Inc (LRMR) with its peers suggests the former has fared considerably weaker in the market. LRMR showed an intraday change of -2.87% in last session, and over the past year, it shrunk by -12.66%%.
Data on historical trading for Larimar Therapeutics Inc (NASDAQ:LRMR) indicates that the trading volumes over the past 10 days have averaged 0.86 and over the past 3 months, they’ve averaged 1.27 million. According to company’s latest data on outstanding shares, there are 64.03 million shares outstanding.
Nearly 43.06% of Larimar Therapeutics Inc’s shares belong to company insiders and institutional investors own 62.17% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 6.49 million shares as on 2025-06-13, resulting in a short ratio of 5.38. According to the data, the short interest in Larimar Therapeutics Inc (LRMR) stood at 1836.00 of shares outstanding as of 2025-06-13; the number of short shares registered in 2025-05-15 reached 9.83 million. The stock has fallen by -61.83% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the LRMR stock heading into the next quarter.
